Amgen has asked the FDA to review evidence that its drug Tavneos (avacopan), which treats a rare form of vasculitis, is worth keeping on the market.
Amgen has asked the FDA to review evidence that its drug Tavneos (avacopan), which treats a rare form of vasculitis, is worth keeping on the …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Amgen Seeks FDA Hearing To Challenge Proposed Tavneos Withdrawal - Amgen (NASDAQ:AMGN)
FDA hearing on Amgen's Tavneos will include findings from an independent review
U.S. FDA Accepts Takeda's Application for Intravenous ENTYVIO® (vedolizumab) in Pediatric Ulcerative Colitis and Crohn's Disease
Sanofi, once on FDA course for speedy approval, gains late expansion for Tzield
As Gilead's Trodelvy stumbles in first-line lung cancer, all eyes turn to Merck, AZ and Daiichi rivals
Takeda AI-Drug Shows Superior Skin Clearance Against Bristol-Myers' Med - Takeda Pharmaceutical Co (NYSE:
FDA Grants Priority Review for Genentech’s Tecentriq for a Certain Type of Stage III Colon Cancer
J&J eyes rare disease expansion for blockbuster-to-be Imaavy with trial win
ADA: Amgen highlights Repatha perks, GLP-1 pitfalls in push to boost cardiometabolic pedigree
Amgen challenges FDA's proposed Tavneos withdrawal, seeks hearing, and cites independent Duke review of trial data.
An independent research firm is reviewing data on Amgen’s Tavneos as the company prepares for a hearing later this month with the…
The FDA wants Amgen's Tavneos off the market. European regulators are investigating data-integrity concerns. And now, a pharma…
The FDA has proposed to withdraw its approval of avacopan for ANCA-associated vasculitis, alleging that employees of the original…
Amgen has taken steps to update its Tavneos label amid an ongoing battle with the FDA.
After the drug’s local license holder called for a brief pause in new patient starts last week, doctors in Japan can once again…
